In the UK, over 25% of adults are living with obesity and ~5million adults have type 2 diabetes. Despite the introduction of preventative programs, the prevalence of these metabolic conditions continues to rise. Although major advances have been made in unravelling the pathophysiology of these conditions, significant heterogeneity exists in the development of complications and responses to treatment. As new medications are being developed and licensed for the management of obesity and type 2 diabetes, there is increased potential for the use of personalised management strategies to achieve and sustain improved outcomes. In this webinar, Dr Shivani Misra, Dr Ben Jones and Professor Sir Stephen O’Rahilly will share clinically relevant insights from their basic science and translational research relating to precision medicine in type 2 diabetes, biased GLP-1 receptor agonism and obesity susceptibility.
